Core Insights - The second-hand housing market in Shenzhen showed strong performance during the recent May Day holiday, with significant increases in transaction volumes compared to the previous year [1][2] - The market is experiencing a mix of increased listings and stable prices, with buyers remaining cautious and seeking better deals [2] Group 1: Market Performance - During the May Day holiday, the second-hand housing transaction volume in Shenzhen increased by 66% year-on-year, while new housing transactions rose by 17% [1] - The number of property viewings for second-hand homes increased by 14% year-on-year, with a notable 27.7% rise in signed contracts from the previous year [1] - From May 1 to May 5, major real estate agencies in Shenzhen recorded 20,684 viewings and facilitated 367 transactions, with 63 contracts signed, marking a 36.96% increase compared to the same period last year [1] Group 2: Market Trends and Buyer Sentiment - There is a notable increase in property listings, with some sellers eager to sell due to market policies and financial pressures, leading to more competitive pricing [2] - The Shenzhen housing market has seen a cooling off from its peak in March, with a 37% year-on-year increase in second-hand transactions, but overall market activity is characterized by a "price for volume" strategy [2] - Expectations for policy support and the introduction of high-quality projects are anticipated to stimulate demand for upgrades and replacements in the housing market [2]

编 辑丨卜羽勤 近日，中国各大航司相继公布2 0 2 4年年报，被戏称为"空中绿皮车"的春秋航空再度凭借"抠门经济学"一骑绝尘。 春秋航空年报显示，2 0 2 4年，该公司实现营收2 0 0 . 0亿元，同比增长11 . 5%；归母净利润2 2 . 7亿元，同比小幅增长 0 . 7%；扣非归母净利润2 2 . 5亿元，同比增长1 . 1%。 作 者丨 陈归辞 相比之下，三大航方面，中国国航、东方航空和南方航空2 0 2 4年虽营收有进，但均面临不同程度亏损，净亏损分别为 2 . 3 7亿元、4 2 . 2 6亿元和1 6 . 9 6亿元；民营航空方面，吉祥航空和华夏航空2 0 2 4年均实现盈利，净利润分别为9 . 1 4亿元 和2 . 6 8亿元。 但 值 得 注 意 的 是，作 为 " 最 赚 钱 的 航 司 "，春 秋 航 空 也 面 临 " 增 收 不 增 利 " 的 问 题，而 这 也 是 行 业 当 前 所 面 临 的 共 性 难 题 。 究其原因，一方面是量增推动收入增长的同时，公司全年客运收益同比回落；另一方面则是由于成本压力。 客运收益方面，2 0 2 4年，春秋航空国内航线的客公里收益为0 ...

Core Viewpoint - The financial performance of Jianfan Biological shows a strong growth in 2024, but a significant decline in Q1 2025 raises concerns about the sustainability of its pricing strategy and reliance on a single product line [1][2]. Financial Performance - In 2024, Jianfan Biological achieved a revenue of 2.677 billion yuan, a year-on-year increase of 39.27%, and a net profit of 820 million yuan, up 87.91% [1]. - The first quarter of 2025 saw a revenue drop to 548 million yuan, a decline of 26.40%, and a net profit decrease to 189 million yuan, down 33.71% [1]. Product and Market Dynamics - The blood purification market shows strong demand, with Jianfan's blood perfusion devices generating 2.504 billion yuan in sales in 2024, a 59.58% increase, accounting for 93.6% of total revenue [3]. - The company has initiated a price reduction strategy, lowering the price of its main product by 26%, which led to a significant increase in sales volume [3][4]. Business Structure and Risks - Jianfan Biological's heavy reliance on blood perfusion devices poses risks, as changes in policy, technology, or market demand could impact operations [4]. - The company is transitioning from a single-product dependency to a diversified product portfolio, including differentiated products in the nephrology field and new growth areas in hepatology and critical care [5]. International Expansion - Jianfan has made strides in international markets, obtaining product approvals in 98 countries, with overseas revenue reaching 59.36 million yuan, representing only 2.2% of total revenue [6]. - The company faces challenges in overcoming technical recognition differences and certification barriers in foreign markets [6]. Competitive Landscape - The potential inclusion of blood perfusion products in centralized procurement could pressure prices, although the company believes that quality and technological leadership will be considered in future procurement policies [7]. - The competitive environment is intensifying, with over 14 domestic companies and international giants entering the blood perfusion market, challenging Jianfan's market share [7]. Future Outlook - For 2025, Jianfan plans to focus on deepening its presence in the domestic blood purification market while expanding internationally, particularly in liver disease and critical care markets [8]. - The company aims to explore new applications for blood perfusion technology in sub-health areas and seek quality acquisition targets through capital market tools [8].

近日，中国各大航司相继公布2024年年报，被戏称为"空中绿皮车"的春秋航空再度凭借"抠门经济学"一 骑绝尘。 春秋航空年报显示，2024年，该公司实现营收200.0亿元，同比增长11.5%；归母净利润22.7亿元，同比 小幅增长0.7%；扣非归母净利润22.5亿元，同比增长1.1%。 相比之下，三大航方面，中国国航、东方航空和南方航空2024年虽营收有进，但均面临不同程度亏损， 净亏损分别为2.37亿元、42.26亿元和16.96亿元；民营航空方面，吉祥航空和华夏航空2024年均实现盈 利，净利润分别为9.14亿元和2.68亿元。 但值得注意的是，作为"最赚钱的航司"，春秋航空也面临"增收不增利"的问题，而这也是行业当前所面 临的共性难题。 "量增价低"致客运收益下降 春秋航空年报显示，2024年，该公司完成运输总周转量456,786.5万吨公里、旅客周转量5,040,445.0万人 公里、运输旅客2,868.0万人次、客座率为91.5%，同比分别上升 18.7%、18.8%、18.8%和2.1个百分点。 前三项达到2019年同期的126.9%、127.0%和 128.1%，客座率较2019年同期上升0.7个 ...

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company reported a revenue of 69.85 billion RMB in Q1, representing a year-on-year growth of 6.9%, and a net profit attributable to shareholders of 2.23 billion RMB, up 16.9% year-on-year, slightly exceeding expectations due to operational model transformation and network optimization [1][2] - The company is expected to benefit from stable profits from express delivery, diversified business growth, and international expansion, leading to a revaluation from an express delivery company to a comprehensive logistics service provider [1][3] Revenue and Volume Growth - The average daily volume of parcels increased by 21.0% year-on-year to 3.56 billion parcels, with total parcel volume growing by 19.7% to 3.54 billion parcels [2] - The average price per parcel decreased by approximately 11.0% year-on-year to 14.55 RMB, continuing the trend of "price for volume" established over the past 24 years [2] Business Segments and Cost Optimization - Revenue from express logistics grew by 7.2% year-on-year, while supply chain and international business revenue increased by 9.9% year-on-year, driven by competitive product offerings and enhanced international network capabilities [2] - The company achieved a gross margin of 13.3%, a slight increase of 0.1 percentage points year-on-year, with gross profit rising by 8.0% to 9.29 billion RMB [2] Profit Forecast and Valuation - The company maintains net profit forecasts of 11.8 billion RMB, 14.2 billion RMB, and 16.0 billion RMB for 2025-2027, with corresponding EBITDA of 34.9 billion RMB, 38.5 billion RMB, and 41.3 billion RMB [3] - The valuation for A-shares is set at 8.0x EV/EBITDA for 2025, above the average of 4.8x for comparable companies, while H-shares are valued at 7.7x EV/EBITDA, also above the average of 5.2x [3]

1999年，杨帆在安徽创立了溜溜果园的前身安徽溜溜果园电子商务有限公司。 2001年，一次偶然的青梅制品研发，成为命运转折点。首款溜溜梅产品虽未被主动主推，却凭借独特风味在区域市场悄然走红。 2006年，杨帆做了个关键决策：停掉所有非梅类生产线，聚焦青梅深加工。这个在当时看似 "孤注一掷"的转型，为后来的品类垄断埋下伏 笔。 2009年，"溜溜果园"品牌正式成立，选址安徽芜湖、福建诏安等青梅核心产区建设工厂，构建起 "从枝头到舌尖" 的初步产业链。 而真正让品牌破圈的是 2013 年的营销战役：邀请杨幂作为代言人，在湖南卫视等平台高频次投放 "魔性"广告，那句重复七次的 "你没事吧" 迅 速形成传播裂变。 数据显示，广告投放当年，溜溜梅销量同比激增200%，营收突破10亿元大关，成为国内首个跻身 "十亿俱乐部" 的青梅零食企业。 "你没事吧？没事就吃溜溜梅！" 这句曾席卷社交媒体的广告语，不仅让杨幂的魔性表情包火遍全网，更让溜溜梅一炮而红。 近期，溜溜梅母公司—溜溜果园集团股份有限公司（以下简称 "溜溜果园"）再次叩响资本市场大门，向港交所递交主板上市申请。距离2019 年A股IPO撤回已过去六年，这家 "中 ...

Core Viewpoint - Haidilao is increasingly adopting a price reduction strategy to attract more customers and adapt to the competitive market environment, introducing smaller portion sizes and lower-priced menu items to cater to the "solitary economy" trend [1][3][6]. Pricing Strategy - Haidilao has launched a "small pot" model priced between 16-22 yuan and introduced 35 types of small dishes priced between 4-25 yuan, aiming to lower the consumption threshold [1][3]. - The average customer spending has decreased from 110.1 yuan in 2020 to 97.5 yuan in 2024, reflecting a shift towards more affordable dining options [4][8]. - The company has implemented various pricing strategies, including high-value meal packages and discounts for students, to maintain customer traffic despite declining average spending [6][8]. Market Trends - The hot pot industry is experiencing a general decline in average spending, with consumer preferences shifting towards value for money, leading to a decrease in average spending from over 80 yuan in late 2023 to below 70 yuan by the end of 2024 [6][8]. - Haidilao's table turnover rate has improved to 4.1 times per day, indicating effective management despite the drop in average spending [6][8]. Expansion and Business Model - In 2024, Haidilao opened 62 new stores but had a net decrease of 6 stores, bringing the total to 1,368 [8]. - The company is cautiously exploring a franchise model to expand its reach while managing costs, with a high entry barrier for potential franchisees [10][11]. - Haidilao has also initiated a diversification strategy, launching multiple new restaurant brands under the "Red Pomegranate Plan" to innovate and expand its market presence [12][14]. Operational Adjustments - The company has decentralized decision-making to regional managers, allowing for localized menu adaptations and improved customer satisfaction [16][17]. - Haidilao is focusing on enhancing customer engagement through unique in-store experiences and personalized service, which may help in retaining customer interest amid competitive pressures [15][17].

Core Insights - The aviation industry continues to exhibit a "price for volume" characteristic, with airlines experiencing lower-than-expected operational efficiency, leading to a situation where passenger numbers are high but financial performance is weak [1][3][19] Pricing Adjustments - Starting April 5, 2025, domestic fuel surcharges will be reduced: 20 yuan for flights over 800 kilometers and 10 yuan for flights 800 kilometers or less, marking a decrease of 20 yuan and 10 yuan respectively compared to previous rates [4][6] - The last adjustment to fuel surcharges occurred in February 2025, which had increased the fees, indicating that the current reduction returns the charges to early-year levels [6] Ticket Pricing Trends - Average ticket prices for the Qingming holiday are approximately 672.9 yuan, reflecting a 2.7% decrease compared to 2019 and a 7.0% decrease compared to 2024 [6] - International ticket prices have also decreased, with flights to destinations like Bangkok and Singapore showing nearly a 10% drop compared to last year [16] Passenger Demand and Flight Volume - Daily passenger volume during the Qingming holiday is expected to reach approximately 1.876 million, a 10.3% increase from 2024, while the growth in flight numbers is smaller, with an expected increase of 5.7% [9] - Among the top 20 airlines, 15 are projected to see year-on-year growth in flight numbers, with some airlines like Tibet Airlines and China National Aviation experiencing significant increases [9] Airport Activity - 38 major airports are expected to see an increase in flight volumes compared to 2024, with Guangzhou Baiyun and Shenzhen Baoan airports showing the highest growth rates [13] Market Dynamics - The international flight market is recovering, with March 2025 seeing nearly 54,000 international flights, reaching 85.5% of pre-pandemic levels [19] - The competition between airlines and high-speed rail is intensifying, leading to a structural shift in passenger demographics, with high-end travelers moving to rail and budget travelers shifting to air travel [22]

北京时间 3 月 19 日下午，安踏（2020.HK）发布了 2024 年全年业绩。由于安踏在今年一月份和去年十月份已经公布过 2024Q3、Q4 的运营表现，因此，市场对于 总收入的预期把握相对较准， 但引发市场担忧的核心点还是在于安踏盈利能力的下降。 具体要点如下： 1.整体业绩：营收小超预期，盈利能力不及预期 ：24H2 公司实现营收 370.9 亿元，同比增长达到 13.4%，与前期公布的零售流水相比，营收端小超市场预期 （356.5 亿元）。毛利率和预期基本一致，但在激烈的市场竞争下，由于公司加大了市场推广力度叠加对现有店铺的升级调改，费用支出高增使得核心经营利润不 及预期。 2、FILA 偏弱，安踏稳健，其他品牌高增： 分品牌看，安踏主品牌实现营收 174.5 亿， 小超 市场预期（170.8 亿）。 海豚君认为主要系安踏主品牌下半年增加了 高性 价比产品的推出，并增加了在高性价比店型——超级安踏中的陈列 。FILA 和市场预期基本一致，中个位数的增长，相较于前两年双位数以上的增长明显回 落。 让海豚君眼前一亮的是其他品牌在高基数下仍然实现了 64% 的高速增长，全年营收超过 100 亿，妥妥成了 ...

Core Viewpoint - Zhaoli Pharmaceutical (300181) reported steady growth in its performance for 2024, with significant revenue and profit increases driven by its core products and effective pricing strategies [1][6]. Financial Performance - In 2024, the company achieved revenue of 2.58 billion yuan, a year-on-year increase of 32.81% - The net profit attributable to shareholders was 505 million yuan, up 31.79% - The non-recurring net profit was 503 million yuan, growing by 34.75% - Earnings per share (EPS) stood at 0.72 yuan [1]. Product Performance - The core product, the Wuling series, showed robust growth, with a revenue increase of 17.14% in 2024 - Wuling capsules saw sales volume and revenue growth of 22.62% and 15.96% respectively, while Lingze tablets experienced sales volume and revenue growth of 23.17% and 22.64% respectively [2][3]. Market Dynamics - The Wuling capsules, a unique product and a national Class I new drug, have maintained stable pricing despite a 21% price drop in 2022 during collective procurement - The product is well-positioned in the market, especially in public grassroots medical terminals, with ongoing research into its application for Alzheimer's disease prevention [3]. Strategic Developments - The Bailing series, including Bailing tablets and capsules, was selected in the national collective procurement, which is expected to enhance competitiveness in various regions - Short-term projections indicate a 15.25% increase in sales for Bailing tablets, although revenue may decrease by 7.23% due to a 3% price drop [4]. Business Growth Areas - The company has effectively leveraged its "one body, two wings" strategy, resulting in a 45.82% revenue increase in traditional Chinese medicine slices and a 145.34% increase in formula granules in 2024 [5]. Profit Forecast - The company is expected to maintain strong performance due to its competitive advantages, effective marketing strategies, and favorable government policies supporting traditional Chinese medicine - Revenue projections for 2024-2026 are 2.596 billion, 3.206 billion, and 3.811 billion yuan respectively, with net profits of 534 million, 713 million, and 912 million yuan [6][7].